1.	Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NLG0301, 1209-1184, NCT01774578
2.	Effects of Selected Vegetable and Herb Mix (SV) on Advanced Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: SV-001 and SV-002, SFC-SV001, SFC-01-0150-0001-02-CM, SFC-01-0150-001, SFC-SV002, NCT00246727
3.	Phase III Randomized Study of Paclitaxel Poliglumex and Carboplatin Versus Paclitaxel and Carboplatin in Women With Chemotherapy-Naïve Stage IIIB or IV or Recurrent Non-Small Cell Lung Cancer and Estradiol > 30 pg/mL. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTI-PGT-07-00400, PGT-06-0040(0), EUDRACT-2007-004167-22, NCT00551733
4.	Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00469, CALGB 30607, CDR0000597649, U10CA031946, NCT00693992
5.	Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: LF-0208, NCT00706862
6.	PF-00299804 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Standard Therapy for Advanced or Metastatic Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Health services research, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: BR26, CAN-NCIC-BR26, PFIZER-CAN-NCIC-BR26, CDR0000657246, NCT01000025
7.	Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000662707, CALGB-30801, NCT01041781
8.	Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000666482, ECOG-E5508, E5508, NCT01107626
9.	A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A8081014, NCT01154140
10.	A Study of First-line Maintenance Tarceva (Erlotinib) Versus Tarceva at Time of Disease Progression in Patients With Advanced Non-small Cell Lung Cancer After Chemotherapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BO25460, NCT01328951
11.	A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MO22097, NCT01351415
12.	A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: OAM4971g, GO27761, 2011-002224-40, NCT01456325
13.	Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: STU 052011-093, NCT01459497
14.	KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: KD019-301, NCT01487174
15.	Study of BMS-936558 Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA209-017, 2011-004792-36, NCT01642004
16.	Study of BMS-936558 Compared to Docetaxel in Previously Treated Advanced or Metastatic Non-squamous NSCLC Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA209-057, 2012-002472-14, NCT01673867
17.	ADAM-Afatinib Diarrhea Assessment and Management Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1200.167, NCT01814553
18.	Study to Evaluate AMG 706 with or without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 20040153, UCLA-0408078-01, AMGEN-20040153, NCT00094835
19.	Hypo-Hyperfractionated Chest Radiation for Non Small Cell Lung Cancer With Taxotere/Xeloda Combination Chemotherapy Phase: Phase II, Phase I Type: Treatment Status: Active Age: No age spcified Sponsor: Other Protocol IDs: Hypo 2, NCT00256841
20.	Azacitidine and MS-275 in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00220, J0658, CDR0000504083, U01CA070095, JHOC-J0658, 7759, NCT00387465
21.	Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000582319, UPCC-806285, UPCC-04507, 806285, NCT00589056
22.	Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-036, NCT00907179
23.	Phase I/II Study of Romidepsin and Erlotinib Hydrochloride in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: SCCC-12508, SCCC-12508, NCT01302808
24.	A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 265-103, NCT00975767
25.	A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MM-121-01-101 (ARD11585), NCT00994123